

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-5. (Cancelled)

6. (Currently Amended) An isolated antibody or fragment thereof that specifically binds to a polypeptide consisting ~~The antibody or fragment thereof of claim 1, wherein the LBP-2 polypeptide consists of the sequence of SEQ ID NO:47 or SEQ ID NO:43.~~

7. (Currently Amended) An isolated antibody or fragment thereof that specifically binds to a polypeptide consisting ~~The antibody or fragment thereof of claim 1, wherein the LBP-2 polypeptide consists of the sequence of SEQ ID NO:2 or SEQ ID NO:7.~~

8. (Currently Amended) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof is comprising an antibody fragment selected from the group consisting of an Fab fragment, an Fab' fragment, or and an F(ab')<sub>2</sub> fragment.

9. (Currently Amended) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof is comprising an antibody fragment selected from the group consisting of an F(v) fragment, a heavy chain monomer, a heavy chain dimer, a heavy chain trimer, a light chain monomer, a light chain dimer, a light chain trimer, or and a dimer consisting of one heavy and one light chain.

10. (Currently Amended) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof comprising an antibody that is a monoclonal antibody.

11. (Currently Amended) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof blocks binding of low density lipoprotein (LDL) ~~LDL~~ to the ~~LBP-2~~ polypeptide.

12-19. (Cancelled)

20. (Currently Amended) A humanized, chimeric, or human antibody or fragment thereof that specifically binds to a polypeptide consisting ~~The antibody or fragment thereof of claim 12, wherein the LBP-2 polypeptide consists of the sequence of SEQ ID NO:47 or SEQ ID NO:43.~~

21. (Currently Amended) A humanized, chimeric, or human antibody or fragment thereof that specifically binds to a polypeptide consisting ~~The antibody or fragment thereof of claim 12, wherein the LBP-2 polypeptide consists of the sequence of SEQ ID NO:2 or SEQ ID NO:7.~~

22. (Currently Amended) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof is ~~comprising an antibody fragment selected from the group consisting of an Fab fragment, an Fab' fragment, or and an F(ab')<sub>2</sub> fragment.~~

23. (Currently Amended) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof is ~~comprising an antibody fragment selected from the group consisting of an F(v) fragment, a heavy chain monomer, a heavy chain dimer, a heavy chain trimer, a light chain monomer, a light chain dimer, a light chain trimer, or and a dimer consisting of one heavy and one light chain.~~

24. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof is a humanized antibody or fragment thereof.

25. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof is a chimeric antibody or fragment thereof.

26. (Original) The antibody or fragment thereof of claim 25, wherein the chimeric antibody or fragment thereof contains a constant region derived from a human antibody and a variable region derived from a mouse antibody.

27. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof is a human antibody or fragment thereof.

28. (Currently Amended) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof blocks binding of LDL to the LBP-2 polypeptide.

29-30. (Cancelled)

31. (Currently Amended) A preparation of polyclonal antibodies that that specifically bind to a polypeptide consisting ~~The preparation of claim 29, wherein the LBP-2 polypeptide consists of the sequence of SEQ ID NO:47 or SEQ ID NO:43.~~

32. (Currently Amended) A preparation of polyclonal antibodies that that specifically bind to a polypeptide consisting ~~The preparation of claim 29, wherein the LBP-2 polypeptide consists of the sequence of SEQ ID NO:2 or SEQ ID NO:7.~~

33. (Currently Amended) The preparation of claim 32, wherein the antibodies block binding of LDL to the ~~LBP-2~~ polypeptide.

34-38. (Cancelled)

39. (Original) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof comprises a label.

40. (Original) The antibody or fragment thereof of claim 39, wherein the label is a radiolabel.

41. (Original) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof comprises a technetium-binding ligand.

42. (Original) The antibody or fragment thereof of claim 7, wherein the antibody or fragment thereof comprises a gadolinium-binding chelator.

43. (Currently Amended) The antibody or fragment thereof of claim 42, wherein the gadolinium-binding chelator is diethylene triamine penta-acetic acid (DTPA) ~~DTPA~~.

44-48. (Cancelled)

49. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof comprises a label.

50. (Original) The antibody or fragment thereof of claim 49, wherein the label is a radiolabel.

51. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof comprises a technetium-binding ligand.

52. (Original) The antibody or fragment thereof of claim 21, wherein the antibody or fragment thereof comprises a gadolinium-binding chelator.

53. (Original) The antibody or fragment thereof of claim 52, wherein the gadolinium-binding chelator is DTPA.

54. (Cancelled)

55. (Original) A pharmaceutical composition comprising the antibody or fragment thereof of claim 7 and a pharmaceutically acceptable carrier.

56. (Cancelled)

57. (Original) A pharmaceutical composition comprising the antibody or fragment thereof of claim 21 and a pharmaceutically acceptable carrier.

58-59. (Cancelled)

60. (Original) A cell line that produces the antibody of claim 7.

61. (Original) The cell line of claim 60, wherein the cell line is a hybridoma.

62-63. (Cancelled)

64. (Original) A cell line that produces the antibody of claim 21.

65. (Original) The cell line of claim 64, wherein the cell line is a hybridoma.

66-71. (Cancelled)

72. (New) A pharmaceutical composition comprising the antibody or fragment thereof of claim 6 and a pharmaceutically acceptable carrier.

73. (New) A pharmaceutical composition comprising the antibody or fragment thereof of claim 20 and a pharmaceutically acceptable carrier.

74. (New) A cell line that produces the antibody of claim 6.

75. (New) The cell line of claim 74, wherein the cell line is a hybridoma.

76. (New) A cell line that produces the antibody of claim 20.

77. (New) The cell line of claim 76, wherein the cell line is a hybridoma.